IDH1 and central nervous system cancer: <h4>Background</h4>Few exceptional responses in cancer treatment were attributed to a genetic predisposition of the tumor.<h4>Methods</h4>We analyzed a cohort of 3105 patients from 12 different cancer types and systematically sought the existence of a correlation between overall survival and the interaction of 21 antineoplastic treatments with 6 tumor mutations.<h4>Results</h4>We identified a single significant correlation resulting in increased overall survival from temozolomide in lower-grade glioma with IDH1 R132H mutations.